NeuVasQ
Private Company
Total funding raised: $3M
Overview
NeuVasQ is a private, preclinical-stage biotech based in Gosselies, Belgium, founded in 2018. The company is developing a novel class of therapeutic antibodies designed to activate the Wnt signaling pathway specifically at the neurovascular unit to repair leaky blood-brain and blood-retina barriers. Its initial focus is on major ophthalmic indications—diabetic macular edema (DME) and wet age-related macular degeneration (wAMD)—with potential expansion into neurological conditions. The company is led by an experienced executive director and is actively presenting preclinical data at scientific conferences.
Technology Platform
Platform for developing first-in-class Gpr124- and Reck-targeting Wnt surrogate antibodies designed to selectively activate Wnt signaling at the neurovascular unit to restore blood-brain and blood-retina barriers.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
In ophthalmology, NeuVasQ competes with dominant anti-VEGF biologics (e.g., aflibercept, ranibizumab), next-generation anti-VEGF, and other novel modalities targeting angiogenesis or inflammation. Its barrier-restoring mechanism is a key differentiator. In the broader neurology space, it would compete with a wide range of drug developers, though direct competitors targeting Gpr124/Reck for barrier repair appear to be limited, representing a first-mover opportunity.